These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26271341)

  • 1. Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
    Theurer JA; Stecho W; Yoo J; Kwan K; Wehrli B; Harry V; Black M; Pinto N; Winquist E; Palma D; Richter S; Barrett JW; Danielle MacNeil S; Fung K; Howlett CJ; Nichols AC
    Pathol Oncol Res; 2016 Jan; 22(1):35-40. PubMed ID: 26271341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
    Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM
    JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutations in head and neck squamous cell carcinoma.
    Qiu W; Schönleben F; Li X; Ho DJ; Close LG; Manolidis S; Bennett BP; Su GH
    Clin Cancer Res; 2006 Mar; 12(5):1441-6. PubMed ID: 16533766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
    Suda T; Hama T; Kondo S; Yuza Y; Yoshikawa M; Urashima M; Kato T; Moriyama H
    BMC Cancer; 2012 Sep; 12():416. PubMed ID: 22994622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
    Al-Amri AM; Vatte C; Cyrus C; Chathoth S; Hashim TM; Mohamed YS; Al Ali R; Alsaid A; Al Ali A
    Cancer Biomark; 2016; 16(3):377-83. PubMed ID: 26889984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
    Song B; Cui H; Li Y; Cheng C; Yang B; Wang F; Kong P; Li H; Zhang L; Jia Z; Bi Y; Wang J; Zhou Y; Liu J; Wang J; Zhao Z; Zhang Y; Hu X; Shi R; Yang J; Liu H; Yan T; Li Y; Xu E; Qian Y; Xi Y; Guo S; Chen Y; Wang J; Li G; Liang J; Jia J; Chen X; Guo J; Wang T; Zhang Y; Li Q; Wang C; Cheng X; Zhan Q; Cui Y
    Oncotarget; 2016 Jan; 7(3):3599-613. PubMed ID: 26528858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
    Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
    Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer.
    Nichols AC; Palma DA; Chow W; Tan S; Rajakumar C; Rizzo G; Fung K; Kwan K; Wehrli B; Winquist E; Koropatnick J; Mymryk JS; Yoo J; Barrett JW
    JAMA Otolaryngol Head Neck Surg; 2013 Jun; 139(6):617-22. PubMed ID: 23787421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
    Nichols AC; Black M; Yoo J; Pinto N; Fernandes A; Haibe-Kains B; Boutros PC; Barrett JW
    BMC Pharmacol Toxicol; 2014 Nov; 15():66. PubMed ID: 25428177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
    Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.
    McBride SM; Rothenberg SM; Faquin WC; Chan AW; Clark JR; Ellisen LW; Wirth LJ
    Head Neck; 2014 Aug; 36(8):1181-8. PubMed ID: 23852799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
    Cai Y; Dodhia S; Su GH
    Oncotarget; 2017 Mar; 8(13):22203-22217. PubMed ID: 28108737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
    Lui VW; Hedberg ML; Li H; Vangara BS; Pendleton K; Zeng Y; Lu Y; Zhang Q; Du Y; Gilbert BR; Freilino M; Sauerwein S; Peyser ND; Xiao D; Diergaarde B; Wang L; Chiosea S; Seethala R; Johnson JT; Kim S; Duvvuri U; Ferris RL; Romkes M; Nukui T; Kwok-Shing Ng P; Garraway LA; Hammerman PS; Mills GB; Grandis JR
    Cancer Discov; 2013 Jul; 3(7):761-9. PubMed ID: 23619167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
    Fenic I; Steger K; Gruber C; Arens C; Woenckhaus J
    Oncol Rep; 2007 Jul; 18(1):253-9. PubMed ID: 17549376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
    Brauswetter D; Dános K; Gurbi B; Félegyházi ÉF; Birtalan E; Meggyesházi N; Krenács T; Tamás L; Peták I
    Virchows Arch; 2016 May; 468(5):579-87. PubMed ID: 26832731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.
    Hatogai K; Fujii S; Kojima T; Daiko H; Doi T; Ohtsu A; Ochiai A; Takiguchi Y; Yoshino T
    BMC Cancer; 2017 Jan; 17(1):36. PubMed ID: 28068934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.